A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence

Genome Biology

Volumn 17, Issue 1, 2016, Pages

  Canisius, Sander ^a   Martens, John W M ^b   Wessels, Lodewyk F A ^a,c,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^d Cancer Genomics Center Netherlands   (Netherlands)

Author keywords

Co occurrence; Computational biology; Mutual exclusivity

Indexed keywords

GROWTH FACTOR; PROTEIN P53; SONIC HEDGEHOG PROTEIN;

AKT1 GENE; AKT3 GENE; ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; DISCRETE INDEPENDENCE STATISTIC CONTROLLING FOR OBSERVATIONS WITH VARYING EVENT RATE; GENE FREQUENCY; GENE INTERACTION; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; NEOPLASM; ONCOGENE; PI3K GENE; PIK3CA GENE; PIK3R1 GENE; PROBABILITY; PTEN GENE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SIMULATION; SOMATIC MUTATION; SOS1 GENE; STATISTICAL MODEL; TUMOR SUPPRESSOR GENE; ALGORITHM; BIOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY;

ALGORITHMS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85006474647     PISSN: 14747596     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/s13059-016-1114-x     Document Type: Article

References (47)

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW. Cancer genome landscapes. Science. 2013; 339(6127):1546-58. doi: 10.1126/science.1235122.
2. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505(7484):495-501. doi: 10.1038/nature12912.
3. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell. 2011; 145(1):30-8. doi: 10.1016/j.cell.2011.03.020.
4. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007; 39(3):347-51. doi: 10.1038/ng1975.
5. Yeang CH, McCormick F, Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J. 2008; 22(8):2605-22. doi: 10.1096/fj.08-108985.
6. Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 2012; 22(2):398-406. doi: 10.1101/gr.125567.111.
7. Vandin F, Upfal E, Raphael BJ. De novo discovery of mutated driver pathways in cancer. Genome Res. 2012; 22(2):375-85. doi: 10.1101/gr.120477.111.
8. Szczurek E, Beerenwinkel N. Modeling mutual exclusivity of cancer mutations. PLoS Comput Biol. 2014; 10(3):1003503. doi: 10.1371/journal.pcbi.1003503.
9. Babur Ö, Gönen M, Aksoy BA, Schultz N, Ciriello G, Sander C, Demir E. Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. Genome Biol. 2015; 16:45. doi: 10.1186/s13059-015-0612-6.
10. Leiserson MD, Wu HT, Vandin F, Raphael BJ. CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. Genome Biol. 2015; 16:160. doi: 10.1186/s13059-015-0700-7.
11. Hua X, Hyland PL, Huang J, Song L, Zhu B, Caporaso NE, Landi MT, Chatterjee N, Shi J. MEGSA: A powerful and flexible framework for analyzing mutual exclusivity of tumor mutations. Am J Hum Genet. 2016; 98(3):442-55. doi: 10.1016/j.ajhg.2015.12.021.
12. Constantinescu S, Szczurek E, Mohammadi P, Rahnenführer J, Beerenwinkel N. TiMEx: a waiting time model for mutually exclusive cancer alterations. Bioinformatics. 2016; 32(7):968-75. doi: 10.1093/bioinformatics/btv400.
13. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, Sikic BI. A network model of a cooperative genetic landscape in brain tumors. JAMA. 2009; 302(3):261-75. doi: 10.1001/jama.2009.997.
14. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, Okamoto A, Urashima M, Smyth GK, Campbell IG, Bowtell DD, Australian Ovarian Cancer Study. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS ONE. 2010; 5(9). doi: 10.1371/journal.pone.0011408.
15. Klijn C, Bot J, Adams DJ, Reinders M, Wessels L, Jonkers J. Identification of networks of co-occurring, tumor-related DNA copy number changes using a genome-wide scoring approach. PLoS Comput Biol. 2010; 6(1):1000631. doi: 10.1371/journal.pcbi.1000631.
16. Milosevic JD, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A, Klampfl T, Harutyunyan AS, Gisslinger H, Gisslinger B, Burjanivova T, Rumi E, Pietra D, Elena C, Vannucchi AM, Doubek M, Dvorakova D, Robesova B, Wieser R, Koller E, Suvajdzic N, Tomin D, Tosic N, Colinge J, Racil Z, Steurer M, Pavlovic S, Cazzola M, Kralovics R. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol. 2012; 87(11):1010-6. doi: 10.1002/ajh.23309.
17. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-9. doi: 10.1038/nature12634.
18. Remy E, Rebouissou S, Chaouiya C, Zinovyev A, Radvanyi F, Calzone L. A modeling approach to explain mutually exclusive and co-occurring genetic alterations in bladder tumorigenesis. Cancer Res. 2015; 75(19):4042-52. doi: 10.1158/0008-5472.CAN-15-0602.
19. Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Borresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C. The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nat Commun. 2016; 7:11479. doi: 10.1038/ncomms11479.
20. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhang CZ, Wala J, Mermel CH, Sougnez C, Gabriel SB, Hernandez B, Shen H, Laird PW, Getz G, Meyerson M, Beroukhim R. Pan-cancer patterns of somatic copy number alteration. Nature Genet. 2013; 45(10):1134-40. doi: 10.1038/ng.2760.
21. Lancaster HO. Significance tests in discrete distributions. J Am Stat Assoc. 1961; 56(294):223-34. doi: 10.2307/2282247.
22. The Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013; 45(10):1113-20. doi: 10.1038/ng.2764.
23. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J, Lawrence MS, Getz G, Bader GD, Ding L, Lopez-Bigas N. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013; 3:2650. doi: 10.1038/srep02650.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. doi: 10.1073/pnas.0506580102.
25. Ulz P, Heitzer E, Speicher MR. Co-occurrence of MYC amplification and TP53 mutations in human cancer. Nat Genet. 2016; 48(2):104-6. doi: 10.1038/ng.3468.
26. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015; 43(Database issue):447-52. doi: 10.1093/nar/gku1003.
27. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994; 370(6490):527-32. doi: 10.1038/370527a0.
28. Gong Y, Zack TI, Morris LG, Lin K, Hukkelhoven E, Raheja R, Tan IL, Turcan S, Veeriah S, Meng S, Viale A, Schumacher SE, Palmedo P, Beroukhim R, Chan TA. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet. 2014; 46(6):588-94. doi: 10.1038/ng.2981.
29. Yan H, Tong J, Lin X, Han Q, Huang H. Effect of the WWOX gene on the regulation of the cell cycle and apoptosis in human ovarian cancer stem cells. Mol Med Rep. 2015; 12(2):1783-8. doi: 10.3892/mmr.2015.3640.
30. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti MA, Sozzi G. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A. 1999; 96(15):8489-92. doi: 10.1073/pnas.96.15.8489.
31. Wang D, Wang L, Zhou J, Pan J, Qian W, Fu J, Zhang G, Zhu Y, Liu C, Wang C, Jin Z, He Z, Wu J, Shi B. Reduced expression of PTPRD correlates with poor prognosis in gastric adenocarcinoma. PLoS ONE. 2014; 9(11):113754. doi: 10.1371/journal.pone.0113754.
32. Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, Ressom H, Jean W, Bigner D, Yan H, Samuels Y, Waldman T. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res. 2008; 68(24):10300-6. doi: 10.1158/0008-5472.CAN-08-3272.
33. Zarubin T, Han J. Activation and signaling of the p38 map kinase pathway. Cell Res. 2005; 15(1):11-8. doi: 10.1038/sj.cr.7290257.
34. Regard JB, Malhotra D, Gvozdenovic-Jeremic J, Josey M, Chen M, Weinstein LS, Lu J, Shore EM, Kaplan FS, Yang Y. Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification. Nat Med. 2013; 19(11):1505-12. doi: 10.1038/nm.3314.
35. He X, Zhang L, Chen Y, Remke M, Shih D, Lu F, Wang H, Deng Y, Yu Y, Xia Y, Wu X, Ramaswamy V, Hu T, Wang F, Zhou W, Burns DK, Kim SH, Kool M, Pfister SM, Weinstein LS, Pomeroy SL, Gilbertson RJ, Rubin JB, Hou Y, Wechsler-Reya R, Taylor MD, Lu QR. The G protein α subunit G αs is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. Nat Med. 2014; 20(9):1035-42. doi: 10.1038/nm.3666.
36. Takabatake Y, Takabatake T, Sasagawa S, Takeshima K. Conserved expression control and shared activity between cognate T-box genes Tbx2 and Tbx3 in connection with Sonic hedgehog signaling during Xenopus eye development. Dev Growth Differ. 2002; 44(4):257-71. doi: 10.1046/j.1440-169X.2002.00640.x.
37. Kann M, Bae E, Lenz MO, Li L, Trannguyen B, Schumacher VA, Taglienti ME, Bordeianou L, Hartwig S, Rinschen MM, Schermer B, Benzing T, Fan CM, Kreidberg JA. WT1 targets Gas1 to maintain nephron progenitor cells by modulating FGF signals. Development. 2015; 142(7):1254-66. doi: 10.1242/dev.119735.
38. Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PT, Tolstorukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, Mesirov JP, Ruffner H, Bouwmeester T, Luchansky SJ, Murtie J, Kelleher JF, Warmuth M, Sellers WR, Roberts CW, Dorsch M. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med. 2010; 16(12):1429-33. doi: 10.1038/nm.2251.
39. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, Cohen EE, Grandis JR, Nguyen QT, Ideker T. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014; 46(9):939-43. doi: 10.1038/ng.3051.
40. Malinowska-Ozdowy K, Frech C, Schönegger A, Eckert C, Cazzaniga G, Stanulla M, zur Stadt U, Mecklenbräuker A, Schuster M, Kneidinger D, von Stackelberg A, Locatelli F, Schrappe M, Horstmann MA, Attarbaschi A, Bock C, Mann G, Haas OA, Panzer-Grümayer R. KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. Leukemia. 2015; 29(8):1656-67. doi: 10.1038/leu.2015.107.
41. Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007; 3(9):161. doi: 10.1371/journal.pgen.0030161.
42. Yu J, Pressoir G, Briggs WH, Vroh Bi I, Yamasaki M, Doebley JF, McMullen MD, Gaut BS, Nielsen DM, Holland JB, Kresovich S, Buckler ES. A unified mixed-model method for association mapping that accounts for multiple levels of relatedness. Nat Genet. 2006; 38(2):203-8. doi: 10.1038/ng1702.
43. Wang YH. On the number of successes in independent trials. Statistica Sinica. 1993; 3(2):295-312.
44. Liu DC, Nocedal J. On the limited memory BFGS method for large scale optimization. Math Prog. 1989; 45(1-3):503-28. doi: 10.1007/BF01589116.
45. Carlson JM, Heckerman D, Shani G. Estimating false discovery rates for contingency tables. Technical Report MSR-TR-2009-53. 2009. http://research.microsoft.com/apps/pubs/default.aspx?id=80571.
46. Bonchi F, Gionis A, Ukkonen A. Overlapping correlation clustering. Knowl Inf Syst. 2013; 35(1):1-32. doi: 10.1007/s10115-012-0522-9.
47. Chang YT, Leahy RM, Pantazis D. Modularity-based graph partitioning using conditional expected models. Phys Rev E. 2012; 85(1):016109. doi: 10.1103/PhysRevE.85.016109.